<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="cre270123" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Exp Dent Res</journal-id><journal-id journal-id-type="iso-abbrev">Clin Exp Dent Res</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2057-4347</journal-id><journal-id journal-id-type="publisher-id">CRE2</journal-id><journal-title-group><journal-title>Clinical and Experimental Dental Research</journal-title></journal-title-group><issn pub-type="epub">2057-4347</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40172147</article-id><article-id pub-id-type="pmc">PMC11963071</article-id>
<article-id pub-id-type="doi">10.1002/cre2.70123</article-id><article-id pub-id-type="publisher-id">CRE270123</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparative Study of the Expressions of Nuclear (&#x02206;EX3) and Cytoplasmic (2B) Survivins in Oral Squamous Cell Carcinoma and Oral Lichen Planus Using Real&#x02010;Time PCR</article-title></title-group><contrib-group><contrib id="cre270123-cr-0001" contrib-type="author"><name><surname>Amirchaghmaghi</surname><given-names>Maryam</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6504-2725</contrib-id><xref rid="cre270123-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cre270123-cr-0002" contrib-type="author"><name><surname>Pakfetrat</surname><given-names>Atessa</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0480-6442</contrib-id><xref rid="cre270123-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cre270123-cr-0003" contrib-type="author"><name><surname>Mohtasham</surname><given-names>Nooshin</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1262-4668</contrib-id><xref rid="cre270123-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cre270123-cr-0004" contrib-type="author"><name><surname>Mohajertehran</surname><given-names>Farnaz</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6266-4281</contrib-id><xref rid="cre270123-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cre270123-cr-0005" contrib-type="author"><name><surname>shakeri</surname><given-names>Mohammad Taghi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8287-9594</contrib-id><xref rid="cre270123-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cre270123-cr-0006" contrib-type="author" corresp="yes"><name><surname>Vazavandi</surname><given-names>Elahe</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7143-2394</contrib-id><xref rid="cre270123-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>elahevazavandi@gmail.com</email><email>hale.ev2012@yahoo.com</email></address></contrib></contrib-group><aff id="cre270123-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Oral and Maxillofacial Diseases Research Center</named-content>
<institution>Mashhad University of Medical Sciences</institution>
<city>Mashhad</city>
<country country="IR">Iran</country>
</aff><aff id="cre270123-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Dental Research Center</named-content>
<institution>Mashhad University of Medical Sciences</institution>
<city>Mashhad</city>
<country country="IR">Iran</country>
</aff><aff id="cre270123-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Social Determinants of Health Research Center</named-content>
<institution>Mashhad University of Medical Sciences</institution>
<city>Mashhad</city>
<country country="IR">Iran</country>
</aff><aff id="cre270123-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Oral and Maxillofacial Medicine, School of Dentistry</named-content>
<institution>Kerman university of Medical Science</institution>
<city>Kerman</city>
<country country="IR">Iran</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold> Elahe Vazavandi (<email>elahevazavandi@gmail.com</email>; <email>hale.ev2012@yahoo.com</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>11</volume><issue seq="83">1</issue><issue-id pub-id-type="doi">10.1002/cre2.v11.1</issue-id><elocation-id>e70123</elocation-id><history>
<date date-type="rev-recd"><day>16</day><month>3</month><year>2025</year></date>
<date date-type="received"><day>21</day><month>9</month><year>2024</year></date>
<date date-type="accepted"><day>19</day><month>3</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 The Author(s). Clinical and Experimental Dental Research published by John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Clinical and Experimental Dental Research</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CRE2-11-e70123.pdf"/><abstract><title>ABSTRACT</title><sec id="cre270123-sec-0010"><title>Objective</title><p>Survivin is used to determine the prognosis and clinical features of premalignant and malignant lesions. The aim of this study was to determine the correlation between the expression of survivin isoforms and clinical outcomes in oral lichen planus and oral squamous cell carcinoma.</p></sec><sec id="cre270123-sec-0020"><title>Materials and Methods</title><p>This cross&#x02010;sectional study examined 119 cases, including oral squamous cell carcinoma (SCC), oral lichen planus (OLP), and healthy margins of lesions. For all lesions, survivin expression was assessed quantitatively and qualitatively using real&#x02010;time polymerase chain reaction. The data were analyzed using SPSS 20.</p></sec><sec id="cre270123-sec-0030"><title>Results</title><p>The expression of survivin&#x02010;&#x02206;EX3 and survivin&#x02010;2B were quantitatively and qualitatively higher in SCC and OLP cases than in healthy mucosa (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). The mean expression of survivin&#x02010;&#x02206;EX3 in erosive OLP (4.95&#x02009;&#x000b1;&#x02009;4.41) was higher than that in nonerosive OLP (2.13&#x02009;&#x000b1;&#x02009;3.32, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). Moreover, the mean expression of both genes was significantly higher in different grades of SCC compared to healthy mucosa (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). There was also a significant correlation between gene expressions (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></sec><sec id="cre270123-sec-0040"><title>Conclusion</title><p>The increased expression of survivin&#x02010;&#x02206;EX3 and survivin&#x02010;2B in OSCC correlates with tumor progression and advanced clinical stages, suggesting a potential prognostic role.</p></sec></abstract><kwd-group><kwd id="cre270123-kwd-0001">gene expression</kwd><kwd id="cre270123-kwd-0002">neoplasm</kwd><kwd id="cre270123-kwd-0003">oral lichen planus</kwd><kwd id="cre270123-kwd-0004">squamous cell carcinoma</kwd><kwd id="cre270123-kwd-0005">survivin</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>The study was supported by the Mashhad University of Medical Sciences (992125).
</institution><institution-id institution-id-type="doi">10.13039/501100004748</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="8"/><word-count count="5485"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:07.04.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="cre270123-sec-0050"><label>1</label><title>Introduction</title><p>Lichen planus refers to a group of chronic mucocutaneous lesions with different etiology and similar clinical appearance and histopathology (MichaelGlick et al.&#x000a0;<xref rid="cre270123-bib-0017" ref-type="bibr">2021</xref>). In the new WHO classification, oral lichen planus (OLP) is a premalignant lesion with the potential to transform into oral squamous cell carcinoma (SCC) (Tsushima et al.&#x000a0;<xref rid="cre270123-bib-0031" ref-type="bibr">2021</xref>).</p><p>In a study in 2008, the prevalence of lichen planus in patients referred to the Dental Clinic at the Faculty of Dentistry of Mashhad University of Medical Sciences in Iran was reported as 18.2% (Pakfetrat et al.&#x000a0;<xref rid="cre270123-bib-0021" ref-type="bibr">2009</xref>). Another study between 2002 and 2014 reported the prevalence of lichen planus in the Iranian population at 5.5% (Bakhtiari et al.&#x000a0;<xref rid="cre270123-bib-0001" ref-type="bibr">2017</xref>). In addition, it was more common in women than in men in the fourth and fifth decades of life (Gonz&#x000e1;lez&#x02010;Moles et al.&#x000a0;<xref rid="cre270123-bib-0007" ref-type="bibr">2021</xref>).</p><p>No clear etiology for lichen planus has been identified, although deficiencies of iron, zinc, calcium, folic acid, vitamins B6 and B12 have been observed in studies (Gholizadeh and Sheykhbahaei&#x000a0;<xref rid="cre270123-bib-0006" ref-type="bibr">2021</xref>; Chen et al.&#x000a0;<xref rid="cre270123-bib-0003" ref-type="bibr">2015</xref>). Folic acid as well as vitamins B6 and B12 play a role in reducing inflammation by converting homocysteine in to methionine, while their deficiency aggravates lichen planus (Chen et al.&#x000a0;<xref rid="cre270123-bib-0003" ref-type="bibr">2015</xref>). The main cause of OLP is the apoptosis of mucosal keratinocyte cells by cytotoxic T lymphocytes (MichaelGlick et al.&#x000a0;<xref rid="cre270123-bib-0017" ref-type="bibr">2021</xref>). Cytotoxic T cells induce apoptosis and activate the caspase cascade in keratinocyte cells through three mechanisms, namly binding to the keratinocyte TNFa receptor, binding via the Fas ligand receptor to the Fas receptor on the surface of keratinocytes, and perforation of the keratinocyte cell membrane by releasing enzymes (Granzyme B and Perforin) (Sugerman et al.&#x000a0;<xref rid="cre270123-bib-0028" ref-type="bibr">2002</xref>; Jan and Chaudhry&#x000a0;<xref rid="cre270123-bib-0008" ref-type="bibr">2019</xref>).</p><p>OLP is a premalignant lesion, which has the potential to transform into SCC. Therefore, early detection of premalignant and malignant lesions is of utmost importance for treatment (Tsushima et al.&#x000a0;<xref rid="cre270123-bib-0031" ref-type="bibr">2021</xref>).</p><p>Survivin acts in the cell nucleus, cytoplasm, and mitochondria (Raj et al.&#x000a0;<xref rid="cre270123-bib-0023" ref-type="bibr">2008</xref>) depending on the isotype involved in cell division, mitosis, and apoptosis (Figure&#x000a0;<xref rid="cre270123-fig-0001" ref-type="fig">1</xref>) (Frassanito et al.&#x000a0;<xref rid="cre270123-bib-0005" ref-type="bibr">2019</xref>). Survivins identified to date include wild survivin (antiapoptotic), survivin&#x02010;2A (proapoptotic), survivin&#x02010;2B (proapoptotic), survivin&#x02010;&#x02206;EX3 (cell division and antiapoptotic), survivin&#x02010;3A (unknown function), and survivin&#x02010;3B (cell division and antiapoptotic) (Johnson and Howerth&#x000a0;<xref rid="cre270123-bib-0009" ref-type="bibr">2004</xref>; Knauer et al.&#x000a0;<xref rid="cre270123-bib-0010" ref-type="bibr">2007</xref>).</p><fig position="float" fig-type="Figure" id="cre270123-fig-0001"><label>Figure 1</label><caption><p>Roll of isotypes of survivin in nuclear and cytoplasm of a normal cell. Survivin has two different functions: 1. Apoptosis: some survivin variants cause activate apoptosis and others inhibit apoptosis. 2. Cell division and mitosis: survivin in the cytoplasm, after phosphorylation enters the nucleus, interacts with Aurora Borealin B kinase form CPC, and perform their role directly in nuclear division (Frassanito et al.&#x000a0;<xref rid="cre270123-bib-0005" ref-type="bibr">2019</xref>). The reason for including the areas adjacent to the tumors is the phenomenon of field cancerization and the fact that molecular changes are known even in the absence of dysplasia at the margins of the lesions.</p></caption><graphic xlink:href="CRE2-11-e70123-g001" position="anchor" id="jats-graphic-1"/></fig><p>There are various studies on the role of survivin in cancer, such as stomach, kidney and ovarian cancers In the case of oral cancer, however, the results are conflicting. With regard to the transformation of premalignant lesions of the oral cavity into malignancy, several markers such as suvivin have been investigated. Nevertheless, few studies have been conducted on the type and role of survivin, although with conflicting results (Sakthivel et al.&#x000a0;<xref rid="cre270123-bib-0025" ref-type="bibr">2020</xref>; Lingam et al.&#x000a0;<xref rid="cre270123-bib-0012" ref-type="bibr">2021</xref>).</p><p>Compared to other methods, real&#x02010;time polymerase chain reaction (PCR) examines genes that express survivin in more detail, resulting in data that are more accurate. In the present study, the intensity of survivin expression in the nucleus and cytoplasm was examined using real&#x02010;time PCR along with the clinical features of SCC and OLP lesions. The aim was to determine and compare the expression of nuclear (&#x02206;EX3) and cytoplasmic (2B) survivin isoforms both quantitatively and qualitatively in OLP, OSCC and healthy mucosa.</p></sec><sec sec-type="materials-and-methods" id="cre270123-sec-0060"><label>2</label><title>Materials and Methods</title><p>This descriptive, analytical cross&#x02010;sectional study was conducted from December 2019 to November 2022 at the Department of Oral and Maxillofacial Diseases as well as the Pathology Laboratory and the Central Laboratory of the Faculty of Dentistry, Mashhad University of Medical Sciences, Iran. The study protocol was approved by the Ethics Committee of Mashhad University of Medical Sciences under the code IR.MUMS.DENTISTRY.REC.1400.028.</p><sec sec-type="methods" id="cre270123-sec-0070"><label>2.1</label><title>Methods</title><p>Formalin&#x02010;fixed paraffin&#x02010;embedded (FFPE) tissue samples were collected from 119 SCC and OLP cases. Samples were collected from the pathology archive on a simple random sampling basis, using a surgical blade other than a laser to biopsy the lesions. Healthy SCC margins and irritation fibromas (IF) were considered as control.</p><p>MichaelGlick et al. (<xref rid="cre270123-bib-0017" ref-type="bibr">2021</xref>) Inclusion criteria were patient demographic information such as age and gender, definitely diagnosed OLP and SCC lesions based on clinical and histopathological criteria, clinical information on OLP lesions (severity of lesions and their clinical appearance), as well as staging and grading of SCC lesions. Adjacent tumor areas were also included in the controls. The reason for this was the phenomenon of field cancerization and the fact that molecular changes are known even in the absence of dysplasia at the margins of the lesions.</p><p>Exclusion criteria were samples with lichenoid reaction, myoma samples with peripheral irritation and hyperplasia of the surface epithelium and amorphous infiltration in the connective tissue, OLP with dysplastic changes, samples with low&#x02010;quality extracted genes or with failed gene expression.</p><p>When studying gene expression patterns in cancer, selecting both tumor and nontumor tissue from the same individual is one of the best options as it eliminates most confounding factors. Therefore, tumor margin tissue from each patient was used as the control sample. This also helped to better understand how the tumor could affect surrounding tissue and identify subtle changes that indicate an increased risk of cancer. This approach highlights the complexity of tumor biology and the need for comprehensive assessment of both tumor and nontumor tissues in cancer research.</p></sec><sec id="cre270123-sec-0080"><label>2.2</label><title>Assessments</title><sec id="cre270123-sec-0090"><label>2.2.1</label><title>Thongprasom Score</title><p>We used Thongprasom scoring, a standard method for scoring OLP lesions to assess the clinical appearance of OLP lesions (Thongprasom&#x000a0;<xref rid="cre270123-bib-0030" ref-type="bibr">2018</xref>). Samples with erosive and bullous clinical appearance were included in the erosive group and those with atrophic, reticular, papular or plaque&#x02010;like appearance without erosion were included in the nonerosive group (Shang et al.&#x000a0;<xref rid="cre270123-bib-0026" ref-type="bibr">2020</xref>).</p></sec><sec id="cre270123-sec-0100"><label>2.2.2</label><title>Grading and Staging in OSCC Lesions</title><p>Definitely diagnosed SCC lesions were graded according to the degree of infiltration of cancer cells into the underlying connective tissue. The lesions were then divided into three groups, namely I, II and III based on histopathological criteria (Neville et al.&#x000a0;<xref rid="cre270123-bib-0020" ref-type="bibr">2016</xref>). Lesions were staged based on TNM classification and according to size, local lymph node involvement, and distant metastasis. To facilitate statistical analysis based on oncology sources, Stages 1 and 2 were classified as early and Stages 3 and 4 as advanced (Mohajertehran et al.&#x000a0;<xref rid="cre270123-bib-0019" ref-type="bibr">2019</xref>).</p></sec></sec><sec id="cre270123-sec-0110"><label>2.3</label><title>Real&#x02010;Time PCR</title><p>Isolation of total RNA was performed using High Pure RNA Paraffin Kit (Roche, Germany) according to the instructions. The purity and concentration of the extracted total RNA was determined using a NanoDrop 2000 spectrophotometer (NanoDrop Technologies, Wilmington, USA).</p><p>Complementary DNA (cDNA) was synthesized using the Thermo Scientific RevertAid First Strand cDNA Synthesis Kit (REF: 22701, Biotech, Addbio, Korea).</p><p>For quantitative expression of survivin, real&#x02010;time PCR (qPCR) was performed using SYBR Green Mix (TQ1110, SMOBIO, Taiwan) with the following targeting primers:</p><p>Survivin &#x02206;EX3 Forward: 5&#x02032;&#x02010;GACGACCCCATGCAAAG&#x02010;3&#x02032;,</p><p>Survivin &#x02206;EX3 Reverse: 5&#x02032;&#x02010;GTGGCACCAGGGAATAAAC&#x02010;3&#x02032;,</p><p>Survivin 2B Forward: 5&#x02032;&#x02010;GATGACGACCCCATTGG&#x02010;3&#x02032;,</p><p>Survivin 2B Reverse: 5&#x02032;&#x02010;TTATGTTCCTCTCGTGATCC&#x02010;3&#x02032;,</p><p>GAPDH Forward: 5&#x02032;&#x02010;TGCACCACCACCTGCTTA&#x02010;3&#x02032;, and</p><p>GAPDH Reverse: 5&#x02032;&#x02010;GATGGCATGGACTGTGGTCAT&#x02010;3&#x02032;.</p><p>The relative expression of RNA was calculated using the Ct values. The expressions for nuclear (&#x02206;EX3) and cytoplasmic (2B) survivins were normalized to the GAPDH reference gene. Gene expressions were compared based on the 2<sup>&#x02212;&#x00394;CT</sup> method. Primers were designed using the Primer Blast database and Runner Gene software.</p><p>Given the test method used in this study, the cutoff value of the desired gene was considered 2, in accordance with similar studies (Dalman et al.&#x000a0;<xref rid="cre270123-bib-0004" ref-type="bibr">2012</xref>). The gene expression was classified into two groups, namely low and high expression.</p><p>Tissue samples were collected from the identified tumors, with tissue edges taken as controls from the unaffected tissue areas. Incisions were made in the tissue edges with a surgical blade and the samples were carefully placed in appropriate containers.</p><p>After transporting the samples to the laboratory, the samples were fixed in formalin solution and then embedded in paraffin. Thin sections were cut from paraffin&#x02010;embedded samples and placed on microscope slides. Tissue sections were routinely stained with conventional dyes, that is, hematoxylin&#x02010;eosin (H&#x00026;E). Stained tissue sections were then examined under a microscope and a pathologist assessed the presence or absence of cancer cells. The results of the microscopic examination were recorded. The tissue samples and reports were saved and archived for possible future use.</p></sec><sec id="cre270123-sec-0120"><label>2.4</label><title>Statistical Analysis</title><p>The data were analyzed using SPSS 20.0. Descriptive statistics were used to describe the data, including centrality, dispersion, and frequency distribution. For quantitative data analysis, the normality of the data was determined using the Kolmogorov&#x02013;Smirnov one&#x02010;sample test. In case of normality, Student's <italic toggle="yes">t</italic>&#x02010;test and one&#x02010;way analysis of variance were used; otherwise, Mann&#x02013;Whitney <italic toggle="yes">U</italic> and Kruskal&#x02013;Wallis tests were used. Pearson's chi&#x02010;square test was used for qualitative data analysis, and Fisher's exact test was used in cases where more than 20% of the expected frequencies were below five. The significance level was set at 0.05.</p></sec></sec><sec sec-type="results" id="cre270123-sec-0130"><label>3</label><title>Results</title><sec id="cre270123-sec-0140"><label>3.1</label><title>Clinical and Demographic Information</title><p>This study included 29 samples of OLP, 44 samples of OSCC, and 46 samples of healthy tissue (16 healthy inflammatory fibrosis, and 30 healthy margins of SCC). The four groups were homogeneous in terms of gender (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.7), but they differed significantly in terms of age (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.02). The buccal mucosa was the most common site in OLP lesions (72%) and the tongue was the most common site of SCC lesions (42.9%). Thirteen OLP samples (44.8%) were erosive and 16 (55.1%) were nonerosive. Twenty&#x02010;eight cases (63.6%) of SCC lesions were in early stage and 16 cases (36.4%) were in advanced stage (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001). In addition, there were 14 samples (31.8%) of Grade I and 15 samples (34.09%) of Grades II and III (Table&#x000a0;<xref rid="cre270123-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="cre270123-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Demographic information of the subjects in the study (<italic toggle="yes">n</italic>&#x02009;=&#x02009;119).</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Gender (<italic toggle="yes">N</italic>) M/F</th><th align="center" valign="bottom" rowspan="1" colspan="1">Age mean&#x02009;&#x000b1;&#x02009;SD</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">SCC</td><td align="center" valign="top" rowspan="1" colspan="1">19:25</td><td align="center" valign="top" rowspan="1" colspan="1">57.48&#x02009;&#x000b1;&#x02009;14.5<xref rid="cre270123-tbl1-note-0003" ref-type="table-fn">*</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OLP</td><td align="center" valign="top" rowspan="1" colspan="1">9:20</td><td align="center" valign="top" rowspan="1" colspan="1">49.93&#x02009;&#x000b1;&#x02009;14.36</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Healthy margin of SCC</td><td align="center" valign="top" rowspan="1" colspan="1">6:10</td><td align="center" valign="top" rowspan="1" colspan="1">59.63&#x02009;&#x000b1;&#x02009;15.20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Healthy margin of IF</td><td align="center" valign="top" rowspan="1" colspan="1">10:20</td><td align="center" valign="top" rowspan="1" colspan="1">49&#x02009;&#x000b1;&#x02009;16.14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="center" valign="top" rowspan="1" colspan="1">119</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="cre270123-tbl1-note-0001"><p>
<italic toggle="yes">Note</italic>: The difference in mean age between the SCC group and other groups was significant.</p></fn><fn id="cre270123-tbl1-note-0002"><p>Abbreviations: IF, irritation fibromas; OLP, oral lichen planus; SCC, squamous cell carcinoma; SD, standard deviation.</p></fn><fn id="cre270123-tbl1-note-0003"><p>*<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.005.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="cre270123-sec-0150"><label>3.2</label><title>Comparison of Gene Expressions Between Groups</title><p>The mean expression of survivin&#x02010;2B in SCC (4.98&#x02009;&#x000b1;&#x02009;4.96) was significantly higher than those in healthy margin of SCC (0.97&#x02009;&#x000b1;&#x02009;1.27, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001), healthy margin of IF (1.17&#x02009;&#x000b1;&#x02009;1.31, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001) and OLP (1.43&#x02009;&#x000b1;&#x02009;1.99, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.004) (Table&#x000a0;<xref rid="cre270123-tbl-0002" ref-type="table">2</xref>). The percentage expression of high survivin&#x02010;2B in SCC (26.0%) was significantly higher than those in healthy margin of SCC (3.0%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.006), healthy margin of IF (5.0%, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001) and OLP (6%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001) (Table&#x000a0;<xref rid="cre270123-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="cre270123-tbl-0002" content-type="Table"><label>Table 2</label><caption><p>Comparison of survivn&#x02010;2B and survivin&#x02010;&#x02206;EX3 expressions in the study groups (qualitative and quantitative).</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">2B exp. mean&#x02009;&#x000b1;&#x02009;SD</th><th align="center" valign="bottom" rowspan="1" colspan="1">2B low exp. <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">2B high exp. <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#x02206;EX3 exp. mean&#x02009;&#x000b1;&#x02009;SD</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#x02206;EX3 low exp <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#x02206;EX3 high exp. <italic toggle="yes">n</italic> (%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">SCC</td><td align="center" valign="top" rowspan="1" colspan="1">4.98&#x02009;&#x000b1;&#x02009;4.96</td><td align="center" valign="top" rowspan="1" colspan="1">18 (40.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">26 (59.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">14.26&#x02009;&#x000b1;&#x02009;16.23</td><td align="center" valign="top" rowspan="1" colspan="1">15 (34.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (69.9%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OLP</td><td align="center" valign="top" rowspan="1" colspan="1">1.43&#x02009;&#x000b1;&#x02009;1.99</td><td align="center" valign="top" rowspan="1" colspan="1">23 (79.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (20.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">3.39&#x02009;&#x000b1;&#x02009;4.04</td><td align="center" valign="top" rowspan="1" colspan="1">16 (55.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (44.8%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Healthy margin of SCC</td><td align="center" valign="top" rowspan="1" colspan="1">0.97&#x02009;&#x000b1;&#x02009;1.27</td><td align="center" valign="top" rowspan="1" colspan="1">13 (81.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (18.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">1.25&#x02009;&#x000b1;&#x02009;1.63</td><td align="center" valign="top" rowspan="1" colspan="1">13 (81.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (18.8%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Healthy margin of IF</td><td align="center" valign="top" rowspan="1" colspan="1">1.17&#x02009;&#x000b1;&#x02009;1.31</td><td align="center" valign="top" rowspan="1" colspan="1">25 (83.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (16.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">1.33&#x02009;&#x000b1;&#x02009;1.34</td><td align="center" valign="top" rowspan="1" colspan="1">25 (83.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (16.7%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="cre270123-tbl2-note-0001"><p>
<italic toggle="yes">Note:</italic> Quantitative analysis: Based on the Kruskal&#x02013;Wallis test, the difference in mean gene expression in four study groups was significant (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001). Bonferroni's post hoc test was used for pairwise comparisons (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001). Qualitative analysis: Based on the chi&#x02010;square test, the difference in the percentage of gene expression in four study groups was significant (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></fn><fn id="cre270123-tbl2-note-0002"><p>Abbreviations: IF, irritation fibromas; OLP, oral lichen planus; SCC, squamous cell carcinoma; SD, standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Furthermore, the mean expression of survivin&#x02010;&#x02206;EX3 in SCC (14.26&#x02009;&#x000b1;&#x02009;16.23) was significantly higher than those in healthy margin of SCC (1.25&#x02009;&#x000b1;&#x02009;1.63, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001), healthy margin of IF (1.33&#x02009;&#x000b1;&#x02009;1.34, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001) and OLP (3.39&#x02009;&#x000b1;&#x02009;4.04, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.004) (Table&#x000a0;<xref rid="cre270123-tbl-0002" ref-type="table">2</xref>). He percentage expression of high survivin&#x02010;&#x02206;EX3 in SCC (69.9%) was significantly higher than those in healthy margins of SCC (18.8%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001) and healthy margin of IF (16.7%, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001). In addition, the percentage expression of high survivin&#x02010;&#x02206;EX3 in OLP (44.8%) was significantly higher than that in healthy margin of IF (16.7%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.02) (Table&#x000a0;<xref rid="cre270123-tbl-0002" ref-type="table">2</xref>).</p><p>The results of general linear and logistic regression models indicated a significant difference between groups in the quantitative and qualitative expression of 2B and &#x02206;EX3 survivins, even after adjusting for the effect of age.</p></sec><sec id="cre270123-sec-0160"><label>3.3</label><title>Gene Expression in OLP Samples</title><p>The mean expression of survivin&#x02010;&#x02206;EX3 in erosive OLP (4.95&#x02009;&#x000b1;&#x02009;4.41) was significantly higher than that in nonerosive OLP (2.13&#x02009;&#x000b1;&#x02009;3.32, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.009) (Table&#x000a0;<xref rid="cre270123-tbl-0003" ref-type="table">3</xref>). According to the results of the Kruskal&#x02010;Wallis test, there was a statistically significant difference in the quantitative expression of surviving&#x02010;&#x02206;EX3 at different Thongprasom scores (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.049).</p><table-wrap position="float" id="cre270123-tbl-0003" content-type="Table"><label>Table 3</label><caption><p>Comparison of quantitative and qualitative distribution of 2B and &#x02206;EX3 gene expressions in the OLP group according to clinical appearance.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Group OLP</th><th align="center" valign="bottom" rowspan="1" colspan="1">2B exp. mean&#x02009;&#x000b1;&#x02009;SD</th><th align="center" valign="bottom" rowspan="1" colspan="1">2B low exp. <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">2B high exp. <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#x02206;EX3 exp. Mean&#x02009;&#x000b1;&#x02009;SD</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#x02206;EX3 low exp. <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#x02206;EX3 high exp. <italic toggle="yes">n</italic> (%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Erosive</td><td align="center" valign="top" rowspan="1" colspan="1">2.14&#x02009;<bold>&#x000b1;</bold>&#x02009;2.76</td><td align="center" valign="top" rowspan="1" colspan="1">9 (69.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (30.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">4.95&#x02009;&#x000b1;&#x02009;4.41</td><td align="center" valign="top" rowspan="1" colspan="1">5 (38.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (61.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nonerosive</td><td align="center" valign="top" rowspan="1" colspan="1">0.84&#x02009;<bold>&#x000b1;</bold>&#x02009;0.69</td><td align="center" valign="top" rowspan="1" colspan="1">14 (87.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (12.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">2.13&#x02009;&#x000b1;&#x02009;3.32</td><td align="center" valign="top" rowspan="1" colspan="1">11 (68.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (31.3%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;Value</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="cre270123-tbl3-note-0001"><p>
<italic toggle="yes">Note:</italic> The Mann&#x02013;Whitney test was used for quantitative analysis of gene expressions (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). Fisher's exact test was used for qualitative analysis of 2B expression (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05) and chi&#x02010;square test was used for that of &#x02206;EX3 gene expression (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></fn><fn id="cre270123-tbl3-note-0002"><p>Abbreviations: OLP, oral lichen planus; SD, standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Nevertheless, the qualitative expressions of survivin&#x02010;2B and surviving&#x02010;&#x02206;EX3 showed no significant association with the clinical appearance or severity of OLP lesions.</p></sec><sec id="cre270123-sec-0170"><label>3.4</label><title>Gene Expression in SCC Samples</title><sec id="cre270123-sec-0180"><label>3.4.1</label><title>Survivin Expression in Different Stages</title><p>The advanced stages of the SCC group showed a mean survivin&#x02010;2B expression of 10.09 (&#x000b1;3.84), compared to the early stages of SCC, which had a mean of 2.06 (&#x000b1;2.57), (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001). Moreover, Fisher's exact test showed that, 35.7% of early&#x02010;stage SCC samples had qualitatively high survivin&#x02010;2B expression, while 100% of advanced&#x02010;stage lesions exhibited high survivin&#x02010;2B expression (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><p>Similarly, the advanced stages of the SCC group showed a mean surviving&#x02010;&#x02206;EX3 expression of 32.76 (&#x000b1;11.08) compared to the early stages of SCC, which had a mean of 3.69 (&#x000b1;6.16) (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001). Furthermore, 46.4% of early&#x02010;stage SCC samples had qualitatively high surviving&#x02010;&#x02206;EX3 expression, whereas 100% of advanced&#x02010;stage SCC lesions exhibited high surviving&#x02010;&#x02206;EX3 expression (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></sec><sec id="cre270123-sec-0190"><label>3.4.2</label><title>Survivin Expression in Different Grades</title><p>The Grade&#x02010;I SCC group showed a mean survivin&#x02010;2B expression of 3.28 (&#x000b1;4.29), compared to Grade&#x02010;II which had a mean of 5/19 (&#x000b1;5/72), and Grade&#x02010;III SCC, which had a mean of 6.63 (&#x000b1;4.57) (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.04).</p><p>High expression of survivin&#x02010;2B was observed in 35.7% of Grade&#x02010;I SCC lesions, compared to 53/3% of Grade&#x02010;II and 86.7% of Grade&#x02010;III lesions (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0/01) (Table&#x000a0;<xref rid="cre270123-tbl-0004" ref-type="table">4</xref>).</p><table-wrap position="float" id="cre270123-tbl-0004" content-type="Table"><label>Table 4</label><caption><p>Comparison of the quantitative and qualitative distribution of survivin&#x02010;2B and survivin&#x02010;&#x02206;EX3 expression in the SCC group with respect to the stage and grade of lesions.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Group SCC</th><th align="center" valign="bottom" rowspan="1" colspan="1">2B exp. mean&#x02009;&#x000b1;&#x02009;SD</th><th align="center" valign="bottom" rowspan="1" colspan="1">low exp. 2B <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">high exp. 2B <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#x02206;EX3 exp. mean&#x02009;&#x000b1;&#x02009;SD</th><th align="center" valign="bottom" rowspan="1" colspan="1">low exp. &#x02206;EX3 <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">high exp. &#x02206;EX3 <italic toggle="yes">n</italic> (%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Early stage</td><td align="center" valign="top" rowspan="1" colspan="1">2.06&#x02009;&#x000b1;&#x02009;2.57</td><td align="center" valign="top" rowspan="1" colspan="1">18 (64.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (35.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">3.69&#x02009;&#x000b1;&#x02009;6.16</td><td align="center" valign="top" rowspan="1" colspan="1">15 (53.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (46.4%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Advanced stage</td><td align="center" valign="top" rowspan="1" colspan="1">10.09&#x02009;&#x000b1;&#x02009;3.84</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (100.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">32.76&#x02009;&#x000b1;&#x02009;11.08</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (100.0%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Grade I</td><td align="center" valign="top" rowspan="1" colspan="1">3.28&#x02009;&#x000b1;&#x02009;4.29</td><td align="center" valign="top" rowspan="1" colspan="1">9 (64.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (35.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">9.93&#x02009;&#x000b1;&#x02009;13.29</td><td align="center" valign="top" rowspan="1" colspan="1">7 (46.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (44.8%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Grade II</td><td align="center" valign="top" rowspan="1" colspan="1">5.19&#x02009;&#x000b1;&#x02009;5.72</td><td align="center" valign="top" rowspan="1" colspan="1">7 (46.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (53.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">16.89&#x02009;&#x000b1;&#x02009;19.72</td><td align="center" valign="top" rowspan="1" colspan="1">7 (46.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (55.2%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Grade III</td><td align="center" valign="top" rowspan="1" colspan="1">6.63&#x02009;&#x000b1;&#x02009;4.57</td><td align="center" valign="top" rowspan="1" colspan="1">2 (13.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (86.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">15.67&#x02009;&#x000b1;&#x02009;15.82</td><td align="center" valign="top" rowspan="1" colspan="1">1 (6.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (93.3%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">*<italic toggle="yes">p</italic> value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0/05</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="cre270123-tbl4-note-0001"><p>
<italic toggle="yes">Note:</italic> Lesion stage analysis: The Mann&#x02013;Whitney test was used for the quantitative analysis of gene expression due to the non&#x02010;normality of the gene expression distribution (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). Fisher's exact test was used for the qualitative analysis of gene expression (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). Lesion grade analysis: For the quantitative analysis of gene expression, the Kruskal&#x02013;Wallis test was used (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). For the qualitative analysis of Survivin&#x02010;2B expression, the Chi&#x02010;square test was used. For the survivin&#x02010;&#x02206;EX3 expression, Fisher's exact test was used (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></fn><fn id="cre270123-tbl4-note-0002"><p>Abbreviations: SCC, squamous cell carcinoma; SD, standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec></sec><sec sec-type="discussion" id="cre270123-sec-0200"><label>4</label><title>Discussion</title><p>In this study, the highest expression of survivin&#x02010;2B and survivin&#x02010;&#x02206;EX3 were observed, both quantitatively and qualitatively, in OSCC lesions. The two gene expressions were also higher in OLP lesions compared to healthy control tissues. There was no significant increase in both gene expressions in erosive OLP lesions at higher Thongprasom scores compared to nonerosive cases at lower Thongprasom scores. Only the increase in the expression of survivin&#x02010;&#x02206;EX3 in erosive OLP at higher Thongprasom scores was quantitatively significant. In the SCC group, a significant association was found between the SCC grade and the quantitative and qualitative expressions of survivin&#x02010;2B as well as the qualitative expression of survivin&#x02010;&#x02206;EX3. At higher stages, quantitative and qualitative expression of both genes was significantly higher in the SCC group. In addition, the two gene expressions were correlated according to results of the Spearman's correlation test.</p><p>Similar to our study, Lipping et al. (<xref rid="cre270123-bib-0013" ref-type="bibr">2010</xref>), De De Maria et al. (<xref rid="cre270123-bib-0016" ref-type="bibr">2009</xref>), and Mishra et al. (<xref rid="cre270123-bib-0018" ref-type="bibr">2015</xref>) reported a significant increase in the quantitative and qualitative expressions of 2B and &#x02206;EX3 survivin in OSCC samples compared to healthy mucosa and similar to our study. The higher expression of Survivin&#x02010;&#x02206;EX3 compared to survivin&#x02010;2B in SCC samples may be linked to P53 mutation, which enhance Survivin&#x02010;&#x02206;EX3 expression and contribute to tumor progression (Mishra et al.&#x000a0;<xref rid="cre270123-bib-0018" ref-type="bibr">2015</xref>). Survivin&#x02010;&#x02206;EX3 facilitates cell transition from the G1 to G2 phase and thus supports cell division and mitosis in SCC cancer cells (Mahotka et al.&#x000a0;<xref rid="cre270123-bib-0015" ref-type="bibr">1999</xref>; Sah and Seniya&#x000a0;<xref rid="cre270123-bib-0024" ref-type="bibr">2015</xref>; Liu et al.&#x000a0;<xref rid="cre270123-bib-0014" ref-type="bibr">2017</xref>). On the other hand, survivin&#x02010;2B plays a role in apoptosis, because it binds to wild survivin (an antiapoptotic survivin) in the cytoplasm and inhibits its action (Mishra et al.&#x000a0;<xref rid="cre270123-bib-0018" ref-type="bibr">2015</xref>). The increased expression of survivin&#x02010;2B in cancer cells can be due to inhibition of mitosis in cancer cell, but due to the mutation of P53 this is not successful (Mahotka et al.&#x000a0;<xref rid="cre270123-bib-0015" ref-type="bibr">1999</xref>; Sah and Seniya&#x000a0;<xref rid="cre270123-bib-0024" ref-type="bibr">2015</xref>). Similar to our results, Rupa Mishara et al. reported a significant positive correlation between the expression of 2B and &#x02206;EX3 survivins (Mishra et al.&#x000a0;<xref rid="cre270123-bib-0018" ref-type="bibr">2015</xref>). In cancer cells, WT, &#x02206;EX3 and 2B survivins have respectively the highest expressions (Mishra et al.&#x000a0;<xref rid="cre270123-bib-0018" ref-type="bibr">2015</xref>). This is perhaps one of the reasons for the increased expression of survivin&#x02010;2B to mitigate the inhibitory effects of apoptosis and aid in the destruction of cancer cells. When survivin&#x02010;2B is mutated, its function also changes and apoptosis does not occur, which extends the lifespan of cancer cells (Temme et al.&#x000a0;<xref rid="cre270123-bib-0029" ref-type="bibr">2005</xref>; Li et al.&#x000a0;<xref rid="cre270123-bib-0011" ref-type="bibr">2005</xref>). Lipping et al. used real&#x02010;time PCR and IHC to examine the relationship between the qualitative expression of survivin and the stage and grade of SCC lesions. They observed a significant increase in survivin expression with increasing tumor stage and grade (Liping et al.&#x000a0;<xref rid="cre270123-bib-0013" ref-type="bibr">2010</xref>). Similarly, in our study, we found that as the SCC stage increased, both gene expressions increased significantly, both quantitatively and qualitatively. With increasing grade, the quantitative expression of 2B and the qualitative expressions of 2B and &#x02206;EX3 also increased significantly. In advanced tumors the balance between mitosis and apoptosis is disturbed in favor of higher mitosis and lower apoptosis (Qi et al.&#x000a0;<xref rid="cre270123-bib-0022" ref-type="bibr">2010</xref>). On the other hand, De Maria et al. (<xref rid="cre270123-bib-0016" ref-type="bibr">2009</xref>) used both real&#x02010;time PCR and IHC and quantitatively examined the expressions of 2B and &#x02206;EX3 survivins in 22 OSCC samples and their healthy margins. They found no significant correlation between the grade and stage of the tumor and the quantitative expression of both survivin genes (De Maria et al.&#x000a0;<xref rid="cre270123-bib-0016" ref-type="bibr">2009</xref>). Mishra et al. qualitatively analyzed 2B and &#x02206;EX3 expressions (fold change) in 75 samples of OSCC, healthy mucosa of SCC and 12 samples of healthy mucosa using real&#x02010;time PCR. They observed no significant association between the increase in survivin expression and the grade and stage. In view of the conflicting results of the studies, it is therefore worthwhile to examine four other survivin isotypes, in addition to the 2B and &#x02206;EX3 survivins, which also play a role in mitosis and apoptosis, to determine the clinical behavior of tumors (Mishra et al.&#x000a0;<xref rid="cre270123-bib-0018" ref-type="bibr">2015</xref>).</p><p>Sugayana et al. (<xref rid="cre270123-bib-0027" ref-type="bibr">2016</xref>) and Sakthivel et al. (<xref rid="cre270123-bib-0025" ref-type="bibr">2020</xref>) used IHC and compared survivin expressions in OLP (with dysplasia and without dysplasia) and healthy mucosa. They found that survivin expression was significantly higher in OLP compared to healthy mucosa. In our study, although the two survivin expressions in OLP were quantitatively and qualitatively higher than in healthy mucosa, only the difference between the qualitative expressions of survivin&#x02010;&#x02206;EX3 in OLP and healthy margin of IF was statistically significant. Such a contradiction may be due to different assessment methods for gene expression (IHC and PCR). In addition, all sampes in the present study had no dysplasia, which may affect the results. The relative increase in survivin expression in OLP can be justified by the fact that the inflammatory cytokines secreted by T lymphocytes in the presence of chronic inflammation can expose P53 to mutation. Because P53 regulates survivin in cells, it increases survivin expression in the mutant state (Chaiyarit et al.&#x000a0;<xref rid="cre270123-bib-0002" ref-type="bibr">2009</xref>).</p><p>Sugayana et al. (<xref rid="cre270123-bib-0027" ref-type="bibr">2016</xref>) and Sakthivel et al. (<xref rid="cre270123-bib-0025" ref-type="bibr">2020</xref>) examined survivin expression in SCC lesions and compared it to that in OLP by immunohistochemistry, IHC) (Liping et al.&#x000a0;<xref rid="cre270123-bib-0013" ref-type="bibr">2010</xref>). Survivin expressions in the SCC group was significantly higher than that in OLP. In our study, the quantitative expression of 2B and &#x02206;EX3 survivins and the qualitative expression of survivin&#x02010;2B were significantly higher in the SCC group than in OLP. As mentioned above, survivin&#x02010;&#x02206;EX3 plays a role in cell division and mitosis. Since cell division and mitosis are more frequent in cancer cells than in non&#x02010;cancer cells, the expression of survivin&#x02010;2B may increase to inhibit or compensate for such indiscriminate cell division (Mahotka et al.&#x000a0;<xref rid="cre270123-bib-0015" ref-type="bibr">1999</xref>; Sah and Seniya&#x000a0;<xref rid="cre270123-bib-0024" ref-type="bibr">2015</xref>; Liu et al.&#x000a0;<xref rid="cre270123-bib-0014" ref-type="bibr">2017</xref>). It is therefore expected that the expression of survivin&#x02010;&#x02206;EX3 and survivin&#x02010;2B is higher in SCC as a malignant lesion than in OLP. Hence, the two genes can be useful to predict malignant changes in OLP.</p><p>Using IHC, Lingam et al. (<xref rid="cre270123-bib-0012" ref-type="bibr">2021</xref>) compared survivin expressions in plaque&#x02010;like, reticular, and erosive OLPs. They showed that survivin expression was significantly higher in erosive OLP than the other two. In our study, the expression of both 2B and &#x02206;EX3 survivins was quantitatively and qualitatively higher in the majority of OLP lesions with erosive appearance than in those with nonerosive appearance. However, only the increase in the quantitative expression of survivin&#x02010;&#x02206;EX3 in erosive lesions was statistically significant (with a mean of 4.95) compared to nonerosive lesions (with a mean of 0.84). In our study, the expression of survivin&#x02010;2B was quantitatively and qualitatively higher in lesions with higher Thongprasom scores (four and five) than in lesions with scores one and two, although the difference was not significant. Nevertheless, we found a significant relationship between the quantitative expression of survivin&#x02010;&#x02206;EX3 and Thongprasom score. Considering that survivin, in particular &#x02206;EX3, is more strongly expressed in erosive OLP and at higher Thongprasom scores, it can be concluded that survivin expression may be a better marker for assessing the severity of OLP lesions and malignant changes. The reason for the increased expression of survivin in erosive OLP may be that erosive OLP is more inflammatory than nonerosive OLP. On the other hand, inflammation and the presence of various cytokines at the site can cause changes in P53, increase survivin expression and make cells more prone to inappropriate mitosis (Chaiyarit et al.&#x000a0;<xref rid="cre270123-bib-0002" ref-type="bibr">2009</xref>).</p><p>The limitations of this study were the small number of samples and the lack of samples with varying degrees of dysplasia. These can be addressed in further studies.</p></sec><sec sec-type="conclusions" id="cre270123-sec-0210"><label>5</label><title>Conclusion</title><p>The significantly different expression of survivin&#x02010;2B and survivin&#x02010;&#x02206;EX3 in different tumor stages and grades shows that the two genes may be useful to predict the behavior of OSCC. The higher expression of survivins in advanced SCC compared to the healthy margin of SCC demonstrates the importance of the two genes for cell differentiation, tumorigenesis and the biological behavior of SCC.</p><p>In general, the increase in the expression of two genes in erosive OLP proves that there is a greater potential for malignant transformation. In addition, survivin&#x02010;&#x02206;EX3 had greater diagnostic value in OLP, while the expression of survivin&#x02010;2B was more related to the clinical behavior of SCC. Further studies are suggested to support these hypotheses.</p></sec><sec id="cre270123-sec-0220"><title>Author Contributions</title><p>Study conceptualization: Atessa Pakfetrat and Maryam Amirchaghmaghi. Data handling: Elahe Vazavandi. Experimental design: Atessa Pakfetrat, Maryam Amirchaghmaghi, Farnaz Mohajertehran, and Nooshin Mohtasham. Analysis and interpretation of data: Mohammad Taghi Shakeri. Provision of study materials and equipment: Elahe Vazavandi and Farnaz Mohajertehran. Study validation: Mohammad Taghi Shakeri and Nooshin Mohtasham. Supervision: Maryam Amirchaghmaghi and Atessa Pakfetrat. Data presentation: Elahe Vazavandi and Mohammad Taghi Shakeri. Draft preparation: Maryam Amirchaghmaghi, Atessa Pakfetrat, and Elahe Vazavandi. Study consultation: Nooshin Mohtasham. Writing and reviewing: Maryam Amirchaghmaghi, Atessa Pakfetrat, and Elahe Vazavandi. Project administration: Maryam Amirchaghmaghi and Atessa Pakfetrat. All authors approved the final version of this article.</p></sec><sec id="cre270123-sec-0240"><title>Ethics Statement</title><p>The study protocol was approved by the Ethics Committee of Mashhad University of Medical Sciences under the code IR.MUMS.DENTISTRY.REC.1400.028.</p></sec><sec sec-type="COI-statement" id="cre270123-sec-0250"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="cre270123-sec-0230"><title>Acknowledgments</title><p>The authors would like to thank the Vice Chancellor for Research of Mashhad University of Medical Sciences (MUMS) for financial support. The results reported in this paper were part of a graduate thesis proposal.</p></ack><sec sec-type="data-availability" id="cre270123-sec-0270"><title>Data Availability Statement</title><p>The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></sec><ref-list content-type="cited-references" id="cre270123-bibl-0001"><title>References</title><ref id="cre270123-bib-0001"><mixed-citation publication-type="journal" id="cre270123-cit-0001">
<string-name>
<surname>Bakhtiari</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>J. B.</given-names>
<surname>Taheri</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Toossi</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Azimi</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Kawosi Nezhad</surname>
</string-name>. <year>2017</year>. &#x0201c;<article-title>Prevalence of Oral Lichen Planus in Iranian Children and Adolescents: A 12&#x02010;Year Retrospective Study</article-title>.&#x0201d; <source>European Archives of Paediatric Dentistry</source>
<volume>18</volume>: <fpage>419</fpage>&#x02013;<lpage>422</lpage>.<pub-id pub-id-type="pmid">29139037</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0002"><mixed-citation publication-type="journal" id="cre270123-cit-0002">
<string-name>
<surname>Chaiyarit</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Jintakanon</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Klanrit</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Siritapetawee</surname>
</string-name>, and <string-name>
<given-names>K.</given-names>
<surname>Thongprasom</surname>
</string-name>. <year>2009</year>. &#x0201c;<article-title>Immunohistochemical Analyses of Survivin and Heat Shock Protein 90 Expression in Patients With Oral Lichen Planus</article-title>.&#x0201d; <source>Journal of Oral Pathology &#x00026; Medicine</source>
<volume>38</volume>, no. <issue>1</issue>: <fpage>55</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">19192050</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0003"><mixed-citation publication-type="journal" id="cre270123-cit-0003">
<string-name>
<surname>Chen</surname>, <given-names>H.&#x02010;M.</given-names>
</string-name>, <string-name>
<given-names>Y.&#x02010;P.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>J. Y.&#x02010;F.</given-names>
<surname>Chang</surname>
</string-name>, <string-name>
<given-names>Y.&#x02010;C.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>S.&#x02010;J.</given-names>
<surname>Cheng</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Sun</surname>
</string-name>. <year>2015</year>. &#x0201c;<article-title>Significant Association of Deficiencies of Hemoglobin, Iron, Folic Acid, and Vitamin B12 and High Homocysteine Level With Oral Lichen Planus</article-title>.&#x0201d; <source>Journal of the Formosan Medical Association</source>
<volume>114</volume>, no. <issue>2</issue>: <fpage>124</fpage>&#x02013;<lpage>129</lpage>.<pub-id pub-id-type="pmid">25557154</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0004"><mixed-citation publication-type="book" id="cre270123-cit-0004">
<person-group person-group-type="editor">
<string-name>
<surname>Dalman</surname>, <given-names>M. R.</given-names>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<surname>Deeter</surname>, <given-names>A.</given-names>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<surname>Nimishakavi</surname>, <given-names>G.</given-names>
</string-name>
</person-group>, and <person-group person-group-type="editor">
<string-name>
<surname>Duan</surname>, <given-names>Z.&#x02010;H.</given-names>
</string-name>
</person-group>, ed. <year>2012</year>. &#x0201c;<part-title>Fold Change and P&#x02010;value Cutoffs Significantly Alter Microarray Interpretations</part-title>.&#x0201d; In <source>BMC Bioinformatics</source>. <publisher-name>Springer</publisher-name>.</mixed-citation></ref><ref id="cre270123-bib-0005"><mixed-citation publication-type="journal" id="cre270123-cit-0005">
<string-name>
<surname>Frassanito</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Saltarella</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Vinella</surname>
</string-name>, et al. <year>2019</year>. &#x0201c;<article-title>Survivin Overexpression in Head and Neck Squamous Cell Carcinomas as a New Therapeutic Target</article-title>.&#x0201d; <source>Oncology Reports</source>
<volume>41</volume>, no. <issue>5</issue>: <fpage>2615</fpage>&#x02013;<lpage>2624</lpage>.<pub-id pub-id-type="pmid">30896830</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0006"><mixed-citation publication-type="journal" id="cre270123-cit-0006">
<string-name>
<surname>Gholizadeh</surname>, <given-names>N.</given-names>
</string-name>, and <string-name>
<given-names>N.</given-names>
<surname>Sheykhbahaei</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>Micronutrients Profile in Oral Lichen Planus: A Review Literature</article-title>.&#x0201d; <source>Biological Trace Element Research</source>
<volume>199</volume>: <fpage>912</fpage>&#x02013;<lpage>924</lpage>.<pub-id pub-id-type="pmid">32533293</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0007"><mixed-citation publication-type="journal" id="cre270123-cit-0007">
<string-name>
<surname>Gonz&#x000e1;lez&#x02010;Moles</surname>, <given-names>M. &#x000c1;.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Warnakulasuriya</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Gonz&#x000e1;lez&#x02010;Ruiz</surname>
</string-name>, et al. <year>2021</year>. &#x0201c;<article-title>Worldwide Prevalence of Oral Lichen Planus: A Systematic Review and Meta&#x02010;Analysis</article-title>.&#x0201d; <source>Oral Diseases</source>
<volume>27</volume>, no. <issue>4</issue>: <fpage>813</fpage>&#x02013;<lpage>828</lpage>.<pub-id pub-id-type="pmid">32144836</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0008"><mixed-citation publication-type="journal" id="cre270123-cit-0008">
<string-name>
<surname>Jan</surname>, <given-names>R.</given-names>
</string-name>, and <string-name>
<given-names>G. S.</given-names>
<surname>Chaudhry</surname>
</string-name>. <year>2019</year>. &#x0201c;<article-title>Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics</article-title>.&#x0201d; <source>Advanced Pharmaceutical Bulletin</source>
<volume>9</volume>, no. <issue>2</issue>: <fpage>205</fpage>&#x02013;<lpage>218</lpage>.<pub-id pub-id-type="pmid">31380246</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0009"><mixed-citation publication-type="journal" id="cre270123-cit-0009">
<string-name>
<surname>Johnson</surname>, <given-names>M. E.</given-names>
</string-name>, and <string-name>
<given-names>E. W.</given-names>
<surname>Howerth</surname>
</string-name>. <year>2004</year>. &#x0201c;<article-title>Survivin: A Bifunctional Inhibitor of Apoptosis Protein</article-title>.&#x0201d; <source>Veterinary Pathology</source>
<volume>41</volume>, no. <issue>6</issue>: <fpage>599</fpage>&#x02013;<lpage>607</lpage>.<pub-id pub-id-type="pmid">15557069</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0010"><mixed-citation publication-type="journal" id="cre270123-cit-0010">
<string-name>
<surname>Knauer</surname>, <given-names>S. K.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Bier</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Schlag</surname>
</string-name>, et al. <year>2007</year>. &#x0201c;<article-title>The Survivin Isoform survivin&#x02010;3B Is Cytoprotective and Can Function as a Chromosomal Passenger Complex Protein</article-title>.&#x0201d; <source>Cell Cycle</source>
<volume>6</volume>, no. <issue>12</issue>: <fpage>1501</fpage>&#x02013;<lpage>1508</lpage>.</mixed-citation></ref><ref id="cre270123-bib-0011"><mixed-citation publication-type="journal" id="cre270123-cit-0011">
<string-name>
<surname>Li</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Ramnath</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Javle</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Tan</surname>
</string-name>. <year>2005</year>. &#x0201c;<article-title>Nuclear or Cytoplasmic Expression of Survivin: What Is the Significance?</article-title>&#x0201d; <source>International Journal of Cancer</source>
<volume>114</volume>, no. <issue>4</issue>: <fpage>509</fpage>&#x02013;<lpage>512</lpage>.<pub-id pub-id-type="pmid">15578717</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0012"><mixed-citation publication-type="journal" id="cre270123-cit-0012">
<string-name>
<surname>Lingam</surname>, <given-names>H. T.</given-names>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Swetha</surname>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Manyam</surname>
</string-name>. <year>2021</year>. &#x0201c;<article-title>Immunohistochemical Evaluation of Survivin in Oral Lichen Planus and Oral Squamous Cell Carcinoma&#x02010;A Retrospective Study</article-title>.&#x0201d; <source>Medicine and Pharmacy Reports</source>
<volume>94</volume>, no. <issue>3</issue>: <fpage>341</fpage>&#x02013;<lpage>347</lpage>.<pub-id pub-id-type="pmid">34430856</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0013"><mixed-citation publication-type="journal" id="cre270123-cit-0013">
<string-name>
<surname>Liping</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Ying</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Mingzhen</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Yuan</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Lei</surname>
</string-name>. <year>2010</year>. &#x0201c;<article-title>Up&#x02010;Regulation of Survivin in Oral Squamous Cell Carcinoma Correlates With Poor Prognosis and Chemoresistance</article-title>.&#x0201d; <source>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology</source>
<volume>110</volume>, no. <issue>4</issue>: <fpage>484</fpage>&#x02013;<lpage>491</lpage>.</mixed-citation></ref><ref id="cre270123-bib-0014"><mixed-citation publication-type="journal" id="cre270123-cit-0014">
<string-name>
<surname>Liu</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Shi</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Yang</surname>
</string-name>, et al. <year>2017</year>. &#x0201c;<article-title>Nuclear Survivin Promoted by Acetylation Is Associated With the Aggressive Phenotype of Oral Squamous Cell Carcinoma</article-title>.&#x0201d; <source>Cell Cycle</source>
<volume>16</volume>, no. <issue>9</issue>: <fpage>894</fpage>&#x02013;<lpage>902</lpage>.<pub-id pub-id-type="pmid">28384094</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0015"><mixed-citation publication-type="journal" id="cre270123-cit-0015">
<string-name>
<surname>Mahotka</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Wenzel</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Springer</surname>
</string-name>, <string-name>
<given-names>H. E.</given-names>
<surname>Gabbert</surname>
</string-name>, and <string-name>
<given-names>C. D.</given-names>
<surname>Gerharz</surname>
</string-name>. <year>1999</year>. &#x0201c;<article-title>Survivin&#x02010;deltaEx3 and Survivin&#x02010;2B: Two Novel Splice Variants of the Apoptosis Inhibitor Survivin With Different Antiapoptotic Properties</article-title>.&#x0201d; <source>Cancer Research</source>
<volume>59</volume>, no. <issue>24</issue>: <fpage>6097</fpage>&#x02013;<lpage>6102</lpage>.<pub-id pub-id-type="pmid">10626797</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0016"><mixed-citation publication-type="journal" id="cre270123-cit-0016">
<string-name>
<surname>De Maria</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Pannone</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Bufo</surname>
</string-name>, et al. <year>2009</year>. &#x0201c;<article-title>Survivin Gene&#x02010;Expression and Splicing Isoforms in Oral Squamous Cell Carcinoma</article-title>.&#x0201d; <source>Journal of Cancer Research and Clinical Oncology</source>
<volume>135</volume>: <fpage>107</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">18642030</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0017"><mixed-citation publication-type="book" id="cre270123-cit-0017">
<string-name>
<surname>MichaelGlick</surname>, <given-names>L. W. B.</given-names>
</string-name>, <string-name>
<given-names>M. S.</given-names>
<surname>Greenberg</surname>
</string-name>, <string-name>
<given-names>P. B.</given-names>
<surname>Lockhart</surname>
</string-name>, and <string-name>
<given-names>S. J.</given-names>
<surname>Challacombe</surname>
</string-name>. <year>2021</year>. <source>Burke's Oral Medicine: Red and White Lesions of the Oral Mucosa</source> (<edition>13th ed.</edition>). <publisher-name>John Wiley &#x00026; Sons, Inc</publisher-name>.</mixed-citation></ref><ref id="cre270123-bib-0018"><mixed-citation publication-type="journal" id="cre270123-cit-0018">
<string-name>
<surname>Mishra</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Palve</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Kannan</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Pawar</surname>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Teni</surname>
</string-name>. <year>2015</year>. &#x0201c;<article-title>High Expression of Survivin and Its Splice Variants Survivin &#x00394;Ex3 and Survivin 2 B in Oral Cancers</article-title>.&#x0201d; <source>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</source>
<volume>120</volume>, no. <issue>4</issue>: <fpage>497</fpage>&#x02013;<lpage>507</lpage>.<pub-id pub-id-type="pmid">26346910</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0019"><mixed-citation publication-type="journal" id="cre270123-cit-0019">
<string-name>
<surname>Mohajertehran</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Ayatollahi</surname>
</string-name>, <string-name>
<given-names>A. H.</given-names>
<surname>Jafarian</surname>
</string-name>, et al. <year>2019</year>. &#x0201c;<article-title>Overexpression of Lactate Dehydrogenase in the Saliva and Tissues of Patients With Head and Neck Squamous Cell Carcinoma</article-title>.&#x0201d; <source>Reports of Biochemistry &#x00026; Molecular Biology</source>
<volume>7</volume>, no. <issue>2</issue>: <fpage>142</fpage>&#x02013;<lpage>149</lpage>.<pub-id pub-id-type="pmid">30805393</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0020"><mixed-citation publication-type="book" id="cre270123-cit-0020">
<string-name>
<surname>Neville</surname>, <given-names>B. W.</given-names>
</string-name>, <string-name>
<given-names>D. D.</given-names>
<surname>Damm</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Allen</surname>
</string-name>, and <string-name>
<given-names>A. C.</given-names>
<surname>Chi</surname>
</string-name>. <year>2016</year>. <source>Oral and Maxillofacial Pathology: Dermatologic Disease</source> (<edition>4th ed.</edition>). <publisher-name>Elsevier Health Sciences</publisher-name>.</mixed-citation></ref><ref id="cre270123-bib-0021"><mixed-citation publication-type="journal" id="cre270123-cit-0021">
<string-name>
<surname>Pakfetrat</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Javadzadeh&#x02010;Bolouri</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Basir&#x02010;Shabestari</surname>
</string-name>, and <string-name>
<given-names>F.</given-names>
<surname>Falaki</surname>
</string-name>. <year>2009</year>. &#x0201c;<article-title>Oral Lichen Planus: A Retrospective Study of 420 Iranian Patients</article-title>.&#x0201d; <source>Medicina Oral, Patologia Oral Y Cirugia Bucal</source>
<volume>14</volume>, no. <issue>7</issue>: <fpage>315</fpage>&#x02013;<lpage>318</lpage>.</mixed-citation></ref><ref id="cre270123-bib-0022"><mixed-citation publication-type="journal" id="cre270123-cit-0022">
<string-name>
<surname>Qi</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Kudo</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Ando</surname>
</string-name>, et al. <year>2010</year>. &#x0201c;<article-title>Nuclear Survivin Expression Is Correlated With Malignant Behaviors of Head and Neck Cancer Together With Aurora&#x02010;B</article-title>.&#x0201d; <source>Oral Oncology</source>
<volume>46</volume>, no. <issue>4</issue>: <fpage>263</fpage>&#x02013;<lpage>270</lpage>.<pub-id pub-id-type="pmid">20138567</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0023"><mixed-citation publication-type="journal" id="cre270123-cit-0023">
<string-name>
<surname>Raj</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Samadashwily</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Li</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Grossman</surname>
</string-name>. <year>2008</year>. &#x0201c;<article-title>Survivin Repression by p53, Rb and E2F2 in Normal Human Melanocytes</article-title>.&#x0201d; <source>Carcinogenesis</source>
<volume>29</volume>, no. <issue>1</issue>: <fpage>194</fpage>&#x02013;<lpage>201</lpage>.<pub-id pub-id-type="pmid">17916908</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0024"><mixed-citation publication-type="journal" id="cre270123-cit-0024">
<string-name>
<surname>Sah</surname>, <given-names>N. K.</given-names>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Seniya</surname>
</string-name>. <year>2015</year>. &#x0201c;<article-title>Survivin Splice Variants and Their Diagnostic Significance</article-title>.&#x0201d; <source>Tumor Biology</source>
<volume>36</volume>, no. <issue>9</issue>: <fpage>6623</fpage>&#x02013;<lpage>6631</lpage>.<pub-id pub-id-type="pmid">26245993</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0025"><mixed-citation publication-type="journal" id="cre270123-cit-0025">
<string-name>
<surname>Sakthivel</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ramamoorthy</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Jeddy</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Singaram</surname>
</string-name>. <year>2020</year>. &#x0201c;<article-title>Evaluation and Expression of Survivin in Potentially Malignant Lesions and Squamous Cell Carcinoma: A Comparative Study</article-title>.&#x0201d; <source>Cureus</source>
<volume>12</volume>, no. <issue>4</issue>: <elocation-id>e7551</elocation-id>.<pub-id pub-id-type="pmid">32382455</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0026"><mixed-citation publication-type="journal" id="cre270123-cit-0026">
<string-name>
<surname>Shang</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Peng</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Chen</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Xu</surname>
</string-name>. <year>2020</year>. &#x0201c;<article-title>Association of Human Papillomavirus With Oral Lichen Planus and Oral Leukoplakia: A Meta&#x02010;Analysis</article-title>.&#x0201d; <source>Journal of Evidence Based Dental Practice</source>
<volume>20</volume>, no. <issue>4</issue>: <elocation-id>101485</elocation-id>.<pub-id pub-id-type="pmid">33303094</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0027"><mixed-citation publication-type="journal" id="cre270123-cit-0027">
<string-name>
<surname>Suganya</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Bavle</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Paremala</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Makarla</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Sudhakar</surname>
</string-name>, and <string-name>
<given-names>V.</given-names>
<surname>Reshma</surname>
</string-name>. <year>2016</year>. &#x0201c;<article-title>Survivin Expression in Oral Lichen Planus: Role in Malignant Transformation</article-title>.&#x0201d; <source>Journal of Oral and Maxillofacial Pathology</source>
<volume>20</volume>, no. <issue>2</issue>: <fpage>234</fpage>&#x02013;<lpage>238</lpage>.<pub-id pub-id-type="pmid">27601815</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0028"><mixed-citation publication-type="journal" id="cre270123-cit-0028">
<string-name>
<surname>Sugerman</surname>, <given-names>P. B.</given-names>
</string-name>, <string-name>
<given-names>N. W.</given-names>
<surname>Savage</surname>
</string-name>, <string-name>
<given-names>L. J.</given-names>
<surname>Walsh</surname>
</string-name>, et al. <year>2002</year>. &#x0201c;<article-title>The Pathogenesis of Oral Lichen Planus</article-title>.&#x0201d; <source>Critical Reviews in Oral Biology and Medicine</source>
<volume>13</volume>, no. <issue>4</issue>: <fpage>350</fpage>&#x02013;<lpage>365</lpage>.<pub-id pub-id-type="pmid">12191961</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0029"><mixed-citation publication-type="journal" id="cre270123-cit-0029">
<string-name>
<surname>Temme</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Diestelkoetter&#x02010;Bachert</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Schmitz</surname>
</string-name>, et al. <year>2005</year>. &#x0201c;<article-title>Increased p21ras Activity in Human Fibroblasts Transduced With Survivin Enhances Cell Proliferation</article-title>.&#x0201d; <source>Biochemical and Biophysical Research Communications</source>
<volume>327</volume>, no. <issue>3</issue>: <fpage>765</fpage>&#x02013;<lpage>773</lpage>.<pub-id pub-id-type="pmid">15649412</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0030"><mixed-citation publication-type="journal" id="cre270123-cit-0030">
<string-name>
<surname>Thongprasom</surname>, <given-names>K.</given-names>
</string-name>
<year>2018</year>. &#x0201c;<article-title>Oral Lichen Planus: Challenge and Management</article-title>.&#x0201d; <source>Oral Diseases</source>
<volume>24</volume>, no. <issue>1&#x02013;2</issue>: <fpage>172</fpage>&#x02013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">29480607</pub-id>
</mixed-citation></ref><ref id="cre270123-bib-0031"><mixed-citation publication-type="journal" id="cre270123-cit-0031">
<string-name>
<surname>Tsushima</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Sakurai</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Uesugi</surname>
</string-name>, et al. <year>2021</year>. &#x0201c;<article-title>Malignant Transformation of Oral Lichen Planus: A Retrospective Study of 565 Japanese Patients</article-title>.&#x0201d; <source>BMC Oral Health</source>
<volume>21</volume>, no. <issue>1</issue>: <fpage>298</fpage>.<pub-id pub-id-type="pmid">34112142</pub-id>
</mixed-citation></ref></ref-list></back></article>